Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 29:6:116.
doi: 10.3389/fmed.2019.00116. eCollection 2019.

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome

Affiliations
Review

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome

Tomonori Oka et al. Front Med (Lausanne). .

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin. On the other hand, in some cases, patients show skin tumors or erythroderma followed by lymph node involvement and rarely visceral organ involvement. SS is a rare, aggressive cutaneous T-cell lymphoma marked by exfoliative erythroderma, lymphadenopathy, and leukemic blood involvement. Because patients with relapsed or refractory MF/SS display a poor prognosis and the current treatment options are characterized by high rates of relapse, there is unmet need for the efficient treatment. This review provides a discussion of the recent and future promising therapeutic approaches in the management of advanced MF/SS. These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus.

Keywords: Sézary syndrome; clinical trial; mycosis fungoides; novel therapeutic agents; peripheral T-cell lymphoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
History of clinical trials of single-agents which have been approved for cutaneous T-cell lymphoma or peripheral T-cell lymphoma by FDA, EMA, or PMDA. The data were collected on March 31, 2019. When the drug was approved as orphan drug from EMA, the comment “orphan” is added. CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma; FDA, food and drug administration; EMA, European medicines agency; PMDA, pharmaceuticals and medical devices agency.
Figure 2
Figure 2
History of clinical trials of single-agents which have not been approved for cutaneous T-cell lymphoma or peripheral T-cell lymphoma by FDA, EMA, or PMDA. The data were collected on March 31, 2019. PI3K δ/γ I, phosphoinositide-3-kinase δ/γ inhibitor.

Similar articles

Cited by

References

    1. Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma. (2003) 44 (Suppl. 3): S49–54. 10.1080/10428190310001623766 - DOI - PubMed
    1. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. . European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer. (2017) 77:57–74. 10.1016/j.ejca.2017.02.027 - DOI - PubMed
    1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. . Survival outcomes and prognostic factors in mycosis fungoides/sézary syndrome: validation of the revised international society for Cutaneous Lymphomas/European Organisation for research and treatment of cancer staging proposal. J Clin Oncol. (2010) 28:4730–9. 10.1200/JCO.2009.27.7665 - DOI - PubMed
    1. Leuchte K, Schlaak M, Stadler R, Theurich S, von Bergwelt-Baildon M. Innovative treatment concepts for cutaneous T-cell lymphoma based on microenvironment modulation. Oncol Res Treat. (2017) 40:262–9. 10.1159/000472257 - DOI - PubMed
    1. Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic stem cell transplant for Mycosis fungoides and sézary syndrome. Dermatol Clin. (2015) 33:807–18. 10.1016/j.det.2015.05.014 - DOI - PubMed

LinkOut - more resources